Lake Street Maintains Buy on Pelthos Therapeutics, Lowers Price Target to $40
Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.
An expert analyst still likes Pelthos but thinks the stock might be worth less money than before. When an expert lowers their price target, it means they see some bumps ahead but still believe in the company.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.